This site is for healthcare professionals. If you are a member of the public or a patient then please visit our Colonoscopy site.

Well-tolerated1-3

PLENVU® had a comparable safety profile to MOVIPREP®1

Over 85% of patients treated with PLENVU® did not experience treatment-related adverse events1-3,7

There were no serious treatment-related adverse events with PLENVU®1-3

The majority of adverse events were mild or moderate1-3

Has the safety profile expected of a PEG bowel preparation4-6

The only common adverse events associated with PLENVU® are vomiting, nausea and dehydration4

The incidence of treatment-related adverse events was comparable across many patient subgroups, and any differences occurred in subgroups with small or imbalanced patient numbers8,9

Please refer to the Summary of Product Characteristics for further information on the safety profile of PLENVU®

Who can you prescribe PLENVU® for?

Patients with mild-to-moderate renal impairment, hepatic impairment, diabetes, mild cardiac insufficiency, inflammatory bowel disease, or diverticular disease received PLENVU® during clinical studies8

PLENVU® can be prescribed without dose adjustments in:4

  • Elderly patients
  • Patients with mild-to-moderate renal impairment
  • Patients with mild-to-moderate hepatic impairment

Adverse events should be reported to your regulatory agency. Adverse events should also be reported to your local distributor or Norgine Limited, Norgine House, Moorhall Road, Harefield, Uxbridge, Middlesex, UB9 6NS, United Kingdom. Email: globalmedinfo@norgine.com